Videos

Janet Kukreja, MD, discusses 5 studies in bladder cancer being presented at the 2022 ASCO Annual Meeting.

Michael S. Cookson, MD, MMHC, discusses 5 studies in prostate cancer being presented at the 2022 ASCO Annual Meeting.

In this video, Adam S. Kibel, MD, discusses the development of transrectal ultrasound-guided prostate biopsy and how prostate biopsy has continued to evolve over the years.

“What would be wonderful is to have a strong, smart triaging system,” says Shirley Lee, CRNP-FNP, MPH.

“I think the one thing that we're hopeful for is that people will start to look at vitamin D as a potential chemoprevention agent,” says Adam B. Murphy, MD, MBA, MSCI.

“Our main finding was that participants who reported food insecurity in the past year were 65%, more likely to experience urge incontinence compared to those who were food secure,” says Chihiro Okada.

Prostate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.

Neal Shore, MD, FACS, reviews the VISION clinical trial in prostate cancer imaging.

A look at the patient profile of a 62-year-old man presenting with reduced urinary flow and hematuria.

"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.

"We wanted to implement an opioid minimization pathway that was easy to follow and successful,” says Aaron Laviana, MD.

The study evaluated holmium laser enucleation of the prostate, open simple prostatectomy, and robotic simple prostatectomy.

Neal Shore, MD, FACS, muses about the unmet needs in metastatic prostate cancer treatment and shares clinical pearls for community oncologists.

A review of whether PARP inhibitors such as olaparib could potentially be used in earlier lines of therapy for mCRPC.

Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.

An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.

Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).

A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.

An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.

Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.

Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.

The study showed that the PSMA-targeting fluorophore IS-002 enabled enhanced intraoperative tumor detection during robotic prostatectomy.

In the PADRES trial, neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

“We found that men with an elevated FSH but a normal semen test were more likely to have a decline in their sperm concentration and their total motile sperm count over time…when compared to men also starting with the normal semen test but with a normal FSH,” says Joshua Halpern, MD.

“It’s an exciting time in UTUC,” says Joseph Jacob, MD.

“A ureteral stent can be bothersome, but it’s quite variable. Some people don’t even feel the stent and some people have severe symptoms,” says Johnathan Harper, MD.

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.

Dr Lawrence Saperstein describes the patient profile of a 78-year-old man with a history of intensity-modulated radiation therapy for adenocarcinoma.

Katie Murray, DO, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube.